Edwards Lifesciences has received CE Mark approval for expanding the use of the Sapien 3 transcatheter heart valve to patients with severe, symptomatic aortic stenosis at intermediate risk for ...

Edwards Lifesciences EW has announced one-year, real-world data on its SAPIEN 3 Ultra RESILIA valve at the PCR London Valves 2024. These data add to the extensive body of evidence on the company’s ...

IRVINE, Calif., April 14, 2025--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the ...

LONDON--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced one-year data highlighting the continued outstanding performance of its SAPIEN 3 Ultra RESILIA valve. The data were presented ...

NEWBURY, May 8 2024 -- Edwards Lifesciences today announced the UK launch of the SAPIEN 3 Ultra RESILIA valve, the only transcatheter aortic heart valve to incorporate the company’s breakthrough ...

A new propensity-matched analysis looking at 5-year clinical outcomes in intermediate-risk patients with severe symptomatic aortic stenosis shows similar rates of all-cause mortality and stroke among ...

The Edwards SAPIEN 3 Transcatheter Pulmonary Valve (“TPV”) system with Alterra adaptive prestent is indicated for use in the management of pediatric and adult patients with extreme pulmonary ...

This is for you, PrimalScript fans: My contacts at Sapien allowed me to leak a few teasers about the next version of PrimalScript that will hit the streets around August 1. The new 2007 release of ...

Please provide your email address to receive an email when new articles are posted on . Edwards Lifesciences has announced that its second-generation transcatheter valve, Sapien XT, has received FDA ...

Edwards Lifesciences ($EW) wants the FDA to approve its Sapien transcatheter heart valve implant for a broader class of patients. Company officials plan to make their ...